“Substance-use screening and interventions in dental practices: survey of practice-based research network dentists regarding current practices, policies and barriers.”, J Am Dent Assoc, vol. 144, no. 6, pp. 627-38, 2013.
, “Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.”, Addiction, vol. 111, no. 8, pp. 1416-27, 2016.
, “NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.”, Contemp Clin Trials, vol. 50, pp. 253-64, 2016.
, “Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.”, Lancet, vol. 391, no. 10118, pp. 309-318, 2018.
, “Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics”, JAMA Network Open, vol. 4, no. 5, p. e2110721, 2021.
, “Successful Implementation of Substance Use Screening in Rural Federally-Qualified Health Centers Identified High Rates of Unhealthy Alcohol, Cannabis, and Tobacco Use”, in The College on Problems of Drug Dependence (CPDD), Minneapolis, MN, 2022.
, “Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A Stepped Wedge Hybrid Type 1 Effectiveness-Implementation Study”, Contemp Clin Trials, vol. 128, p. 107148, 2023.
,